Guiding the right patients to prostate biopsy.
A simple, non-invasive, urine-based liquid biopsy test. Exosomes from the urine are analyzed to determine a patient’s risk of high-grade prostate cancer.
The EPI score provides a binary cut-point risk stratification, that is part of the shared decision-making process.
The test has been validated in two “real-world” studies.
The test results are available for physicians 3-5 days after the sample is received by our laboratory.
The sample is analyzed in a CLIA certified laboratory.
The EPI test does not require a DRE to be performed before providing a sample. It is a completely non-invasive liquid biopsy test.